Company Encyclopedia
View More
name
Rafael-B
RFL.US
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells.
4.615 T
RFL.USMarket value -Rank by Market Cap -/-

Financial Score

17/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking89/185
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-39.48%E
    • Profit Margin-3044.70%E
    • Gross Margin96.25%A
  • Growth ScoreA
    • Revenue YoY47.63%A
    • Net Profit YoY21.24%B
    • Total Assets YoY19.97%A
    • Net Assets YoY15.24%A
  • Cash ScoreB
    • Cash Flow Margin-3.28%D
    • OCF YoY47.63%A
  • Operating ScoreE
    • Turnover0.01E
  • Debt ScoreA
    • Gearing Ratio15.37%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Chmn Jonas Surrenders 9,867 Of Rafael Holdings Inc [RFL]

    Jonas Howard S, Chairman of Rafael Holdings Inc, surrendered 9,867 shares back to the company to cover option exercise costs and tax liabilities. This transaction was disclosed in a Form 4 filed with the SEC on December 16, 2025. His ending holdings are 14,787,818 shares, with 257,840 direct and 14,529,978 indirect.

    Reuters·
    US
    RFL
    +2.03%
    Reuters·
    US
    RFL
    +2.03%

    Rafael-B | 10-Q: FY2026 Q1 Revenue: USD 240 K

    LB filings·
    US
    RFL
    +2.03%
    LB filings·
    US
    RFL
    +2.03%

    Rafael-B | 8-K: FY2026 Q1 Revenue: USD 240 K

    LB filings·
    US
    RFL
    +2.03%
    LB filings·
    US
    RFL
    +2.03%

    RFL Q1 R&D expenses rose nearly sixfold to USD 7.5 million

    Rafael Holdings Inc. reported Q1 2026 financial results with revenue of USD 0.2 million and a net loss of USD 9.8 million, or USD 0.19 per share. The net loss increased due to Cyclo Therapeutics' expenses post-acquisition. R&D expenses rose nearly sixfold to USD 7.5 million. General and administrative expenses increased by 13% to USD 2.8 million. Cash and cash equivalents stood at USD 45.5 million as of October 31, 2025.

    Reuters·
    US
    RFL
    +2.03%
    Reuters·
    US
    RFL
    +2.03%

    Rafael-B | 10-K: FY2025 Revenue: USD 917 K

    LB filings·
    US
    RFL
    +2.03%
    LB filings·
    US
    RFL
    +2.03%
    © 2025 Longbridge｜Disclaimer